On the latest episode of The Cancer SIGNAL podcast, Kevin McFarland, a lieutenant with his local fire department, shares how a multi-cancer early detection (MCED) test led to a stage 1 diagnosis—even though he was asymptomatic—and helped him gain a new appreciation for his health and family. The Cancer SIGNAL is available wherever you listen to podcasts. #EarlyCancerDetection #MCED Apple Podcasts: https://apple.co/49VeHz8 Spotify: https://bit.ly/3MdT1Ey Transcripts and more: https://bit.ly/48PiKfd
GRAIL
Biotechnology Research
Menlo Park, CA 102,118 followers
Detect cancer early, when it can be cured.
About us
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit grail.com. Community Guidelines: https://bit.ly/3xigb24
- Website
-
http://www.grail.com
External link for GRAIL
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Menlo Park, CA
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Cancer Detection, Cancer Biology, Clinical Trials, Computer Science, Machine Learning, and Data Science
Locations
-
Primary
Get directions
1525 O'Brien Drive
Menlo Park, CA 94025, US
Employees at GRAIL
Updates
-
We are looking forward to presenting our abstract with the University of California San Diego at the upcoming #SUO2025 meeting. This abstract will reveal findings on the use of cell-free DNA methylation in pre-op urine and plasma as a non-invasive method for detecting urothelial carcinoma. Meet us in Phoenix: http://bit.ly/4qNzLgT #UrologicOncology #CancerScreening
-
-
On Pancreatic Cancer Awareness Day, we’re calling attention to the fact that detecting this cancer is not always that simple. Because early-stage pancreatic tumors often go undetected on imaging scans, many people don’t receive a diagnosis until the cancer has already metastasized elsewhere in the body. Consequently, the 5-year survival rate for people with distant disease is only 2.9% compared to 39.4% for those whose cancer has remained localized. By 2030, pancreatic cancer is estimated to be the second-leading cause of cancer death in the US, highlighting the importance of early detection. #PancreaticCancerAwareness #EarlyCancerDetection
-
-
Grateful for the opportunity to meet with the leadership of Conquer Cancer, the ASCO Foundation and American Society of Clinical Oncology (ASCO) and discuss our shared commitment to improving outcomes for people affected by cancer. Thank you for your time and continued leadership in pushing the field forward. Early detection remains one of the greatest opportunities we have to meaningfully change the status quo—and contributions from across the oncology community are essential to making that a reality. At GRAIL, we’re proud to work alongside organizations like Conquer Cancer and ASCO who are deeply committed to innovation and improving care. Together, we can work to find more cancers early when they are more treatable and potentially even curable. Thank you for the work you do every day—for patients, families, clinicians, and the future of cancer care.
-
-
GRAIL employees recently participated in Blood Cancer United's Light the Night events to honor and remember loved ones affected by blood cancer. It was inspiring to see so many people come together with hope, compassion, and strength lighting the way. Thank you to everyone who participated, donated, and helped make this moment so meaningful. Together, we continue to shine a light for those we’ve lost and for those still fighting.
-
-
-
-
-
+1
-
-
Extending our appreciation to John Hancock and Home Base for providing access to multi-cancer early detection testing for special operations veterans. It’s inspiring to collaborate on initiatives that support those who’ve served our country. Rx only. See Important Safety Information: https://lnkd.in/d_fp9JR5
For the second year in a row, we’re proud to provide free access to GRAIL's multi-cancer early detection test, Galleri, to active-duty and veteran special operations service members receiving care through Home Base, in collaboration with Mass General Brigham’s Cancer Early Detection and Diagnostics Clinic. We made the announcement last week during Home Base’s annual “Helping Veterans Heal” telethon with WCVB Channel 5, where a number of our colleagues came together to help answer calls and share our mission to help people live longer, healthier, better lives. We also donated $25,000 to Home Base, a nonprofit dedicated to healing the invisible wounds of war for veterans and their families, to support their continued efforts.
-
-
Today GRAIL reported third quarter 2025 financial results. Learn more: https://bit.ly/47RXsfr
-
-
In honor of Veterans Day, we’re resharing an episode of The Cancer SIGNAL podcast featuring Charles Atwood, MD, from the VA Pittsburgh Healthcare System. Dr. Atwood discussed: ✔️ Why veterans face higher risks for cancer ✔️ How early cancer detection could transform outcomes ✔️ The promise of multi-cancer early detection (MCED) for the future of medicine The Cancer SIGNAL is available wherever you listen to podcasts: https://bit.ly/3Gkmp6Y #EarlyCancerDetection #MCED #VeteransHealth #TheCancerSIGNAL
-
GRAIL reposted this
As the multi-cancer early detection (MCED) field evolves, it is essential that a test must have demonstrated performance in a prospective trial in the intended-use population. To understand whether the Galleri® MCED test provides a meaningful benefit at population scale, we needed a randomised controlled trial to evaluate whether screening with Galleri improves outcomes in real-world practice. That is why we launched the NHS-Galleri trial in England in 2021. The NHS-Galleri trial - the only population-scale randomised controlled trial of an MCED test - is evaluating annual screening with Galleri alongside standard NHS cancer care. As we look ahead to the main trial results in 2026, I've outlined what to expect from the NHS-Galleri trial and why the trial was designed the way it was.
-
Join us next Thursday for GRAIL’s Analyst Day 2025. Register and watch the live webcast here: https://bit.ly/47K19Ue
-